Uncategorized
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3
The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also noting last year’s Phase 3 failure in chronic obstructive pulmonary disease. Read More